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Abstract
Background: The aim was to investigate the comorbidity profile of people with dementia and examine the associations
between severity of comorbidity, health-related quality of life (HRQoL) and quality of life (QoL).
Methods: The improving the experience of Dementia and Enhancing Active Life (IDEAL) cohort consisted of 1,547 peo-
ple diagnosed with dementia who provided information on the number and type of comorbid conditions. Participants also
provided ratings of their health-related and dementia-specific QoL.
Results: The majority of the sample were living with more than one chronic condition. Hypertension was commonly
reported and frequently combined with connective tissue disease, diabetes and depression. The number of comorbid condi-
tions was associated with low QoL scores, and those with severe comorbidity (≥5 conditions) showed the greatest impact
on their well-being.
Conclusions: Comorbidity is an important risk factor for poor QoL and health status in people with dementia. Greater
recognition of the nature and impact of comorbidity is needed to inform support and interventions for people with demen-
tia and a multidisciplinary approach to care provision is recommended.
Keywords: Alzheimer’s, multimorbidities, depression, older people
Living with dementia poses many challenges for people with
dementia and for those who care for them. This may be
coupled with other health problems as the accumulation of
changes associated with ageing can lead to the accrual of ill-
nesses and disabilities [1]. With the increased prevalence of
individual health conditions associated with ageing [2], there is
growing interest in the co-occurrence of medical conditions
and the implications for the individual. Multimorbidity and
comorbidity are used interchangeably to describe the presence
of co-occurring diseases but definitions vary across studies.
Multimorbidity is the co-occurrence of two or more diseases
or active health conditions that may or may not be linked by a
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causal relationship or with no consistent dominant index dis-
order. Comorbidity is the term given to the presence of condi-
tions existing concurrently with a condition considered as the
primary or index disease [1] and this study will focus on the
presence of conditions in addition to dementia as the index
condition. Comorbidities significantly associated with dementia
include physical health conditions such as congestive cerebro-
vascular disease, and cardiac arrhythmia [3], hypertension and
diabetes [4], and depression [5].
People with dementia are more likely to have five or
more health conditions and more prescription usage than
those without dementia [6], and comorbidity ranging from
two to eight conditions has been reported [7]. Examination
of the medical records in England showed that 92% of peo-
ple with dementia had a formal diagnosis of at least one
other disease, and 53% were considered to have comorbid-
ity with three or more conditions [2]. Similarly, 61% of peo-
ple with Alzheimer’s disease across various care settings
had three or more conditions [8]. Comorbidity rates were
the same for people with dementia compared with those
without dementia in a primary care [7], but for care home
residents, rates were higher in people with dementia com-
pared with older care residents without dementia [9]. There
is growing interest not only in the number of comorbid
conditions but also in the combinations or array of condi-
tions referred to as ‘morbidotypes’ [10].
Comorbidity can influence a range of health outcomes
such as mortality [11] and disability [12]. Multimorbidity is
negatively associated with health-related quality of life
(HRQoL) [9, 13], and certain disease combinations, such as
diabetes and coronary disorders, impact more on HRQoL
than others [14]. Higher comorbidity in people with demen-
tia is negatively associated with ratings of disease-specific
QoL [15]. Generally there is a negative association between
comorbidity and QoL but the results are not conclusive,
with variable findings related to QoL and HRQoL [16], and
few studies examining both perceptions of health-related
QoL and well-being.
People with dementia are living with comorbidity, and
greater recognition of the extent and impact of this burden
of disease is essential for the identification of interventions
to help maintain independence and improve QOL [17].
Comorbidity poses significant challenges for care provision,
and greater coordination of care planning across conditions
is needed [4, 18]. The aim of this study is to investigate the
comorbidity profile of people with dementia and to exam-
ine the associations between severity of comorbidity,
HRQoL and QoL using a large community-based cohort of
people with dementia.
Method
Sample
Participants were drawn from the baseline wave of the
‘Improving the experience of Dementia and Enhancing
Active Life’ (IDEAL) longitudinal cohort study recruited
across Great Britain [19]. Inclusion criteria included a clin-
ical diagnosis of dementia and a Mini-Mental State
Examination (MMSE) score ≥15 [20]. Interviews were con-
ducted in participant homes. Analysis is based on V2 of the
IDEAL baseline (T1) dataset.
Ethics statement
Written informed consent was secured for all participants.
Ethics approval was granted by the Wales Research Ethics
Committee 5 (reference 13/WA/0405) and the Ethics
Committee of the School of Psychology, Bangor University
(reference 2014–11684). The IDEAL study is registered
with UKCRN, registration number 16593.
Measures
Information on the age profile, diagnostic subtypes and
educational level of the cohort was included in analyses.
Comorbidity
A record of the presence or absence of 23 chronic condi-
tions was collected using the Charlson comorbidity index
(CCI) [21], administered through a joint interview with the
person with dementia and carer where available. The CCI
included diseases selected on the basis of their association
with mortality and this version of the CCI includes depres-
sion, hypertension, ulcers and use of warfarin [21]. A count
of the diseases within the index is used as a measure of
comorbidity, and as we were interested in the impact of dis-
eases in addition to our index condition dementia was not
counted in the analysis. Comorbidity was categorised into
four levels of severity: no comorbidity, mild (1–2 conditions),
moderate (3–4 conditions) and severe (≥5 conditions).
Health-related quality of life
Participants rated their HRQoL using the two parts of the
EQ-5D-3L [22]:
• The EQ-5D-3L descriptive system has five dimensions:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. The EQ-5D dimensions were dichot-
omised into ‘no problems’ and ‘moderate/severe pro-
blems’ for logistic regression analyses.
• The EQ-5D visual analogue scale (EQ-5D VAS) provides
a self-rating of health on a vertical visual analogue scale
from 0 = ‘worst imaginable health state’ to 100 = ‘best
imaginable health state’. This is used as a quantitative
measure of HRQoL.
Quality of life
The QoL in Alzheimer’s disease (QoL-AD) scale was devel-
oped specifically for people with dementia and focuses on
QoL domains important in cognitively impaired older peo-
ple. Participants rate aspects of their current situation such
as mood, memory and make a global assessment of QoL as
S. M. Nelis et al.
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a whole [23]. Scale scores range from 13 to 52, with higher
scores representing greater QoL.
Statistical analyses
The analysis first investigated the frequencies and preva-
lence of different conditions and their combinations. Linear
regression was conducted to investigate the associations
between severity of comorbidity and both HRQoL and
QoL-AD. The associations between severity of comorbidity
and the five individual dimensions of the EQ-5D were
examined using logistic regression. The models were
adjusted for participants’ sociodemographic characteristics
including age, gender, education and dementia subtype.
Results
The IDEAL cohort consisted of 1,547 people diagnosed
with dementia at baseline; 56.3% were males. The mean
MMSE score was 24.15 (s.d. 3.46; range 14–30). The mean
age of the people with dementia was 76.4 (s.d. 8.5). The
majority of the sample had a diagnosis of Alzheimer’s dis-
ease (55.5%). Characteristics of the sample are presented in
Table 1.
The average HRQoL score was 71.93 (s.d. 18.61), with
an average QoL-AD score of 36.77 (s.d. 5.92). Information
on the EQ-5D domains is shown in Table 1, with moderate
or severe difficulties reported with mobility (41.8%), self-
care (17.2%), performance of usual activities (34%), pain
(40.2%) and anxiety or depression (34%).
Prevalence and combinations of comorbid
conditions
The median number of comorbid conditions reported was 1,
with a range from 0 to 9. The prevalence of the individual
comorbid conditions included in the CCI for the whole sam-
ple and by gender is shown in Figure 1. The five most
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Demographic characteristics of the sample and level of comorbid conditions
Characteristics N (%) Comorbid conditions, N (%), missing (n = 85)
0 1–2 3–4 ≥5
None Mild Moderate Severe
N 1,547 365 (25) 757 (52) 259 (17) 81 (5)
Age groups
<65 136 (8.8) 48 (13.2) 60 (7.9) 14 (5.4) 10 (12.3)
65–69 178 (11.5) 44 (12.0) 95 (12.5) 23 (8.8) 10 (12.3)
70–74 260 (16.8) 70 (19.2) 122 (16.2) 39 (15.0) 13 (16.1)
75–79 370 (23.9) 83 (22.7) 184 (24.3) 62 (23.9) 21 (25.9)
80+ 603 (38.9) 120 (32.9) 296 (39.1) 122 (46.7) 27 (33.3)
Sex
Male 872 (56.3) 198 (54.2) 430 (56.8) 143 (55.2) 54 (66.6)
Female 675 (43.6) 167 (45.7) 327 (43.2) 116 (44.7) 27 (33.3)
Dementia diagnosis
Alzheimer’s disease 858 (55.5) 246 (67.4) 435 (57.5) 108 (41.7) 34 (41.9)
Vascular dementia 171 (11.0) 21 (5.7) 64 (8.5) 56 (21.6) 18 (22.2)
Mixed (Alzheimer’s and vascular) 326 (21.0) 45 (12.2) 161 (21.3) 73 (28.2) 25 (30.8)
Frontotemporal dementia 54 (3.5) 20 (5.5) 26 (3.4) 6 (2.3) 0 (0.0)
Parkinson’s disease dementia 44 (2.8) 8 (2.2) 25 (3.3) 4 (1.5) 2 (2.5)
Lewy body dementia 53 (3.4) 15 (4.1) 26 (3.4) 7 (2.7) 2 (2.7)
Unspecified/Other 41 (2.7) 10 (2.7) 20 (2.6) 2 (2.5) 0 (0.0)
Quality of life measures
QoL-AD total score, mean (SD) 36.7 (5.9) 38.6 (5.7) 37.1 (5.6) 34.5 (5.8) 32.7 (5.4)
EQ-5D VAS, mean (SD) 71.9 (18.6) 77.7 (16.7) 72.5 (17.8) 66.5 (19.3) 59.9 (21.5)
EQ-5D problems, N (%)
Mobility
None 897 (58.1) 280 (77.1) 458 (60.6) 101 (39.0) 14 (17.3)
Moderate/Severe 646 (41.8) 83 (22.8) 297 (39.3) 158 (61.0) 67 (82.7)
Self-care
None 1,209 (82.8) 331 (90.9) 643 (84.2) 187 (72.0) 48 (59.2)
Moderate/Severe 252 (17.2) 33 (9.1) 114 (15.6) 72 (27.8) 33 (40.7)
Usual activities
None 1,018 (66.1) 277 (76.3) 532 (70.6) 140 (54.2) 27 (33.3)
Moderate/Severe 522 (33.9) 86 (23.7) 221 (29.3) 118 (45.7) 54 (66.6)
Pain/Discomfort
None 924 (59.8) 276 (75.8) 456 (60.3) 120 (46.5) 20 (24.7)
Moderate/Severe 620 (40.2) 88 (24.2) 300 (39.7) 138 (53.4) 61 (75.3)
Anxiety/Depression
None 1,014 (65.8) 260 (71.4) 518 (68.7) 144 (56.0) 38 (46.9)
Moderate/Severe 526 (34.2) 104 (28.6) 236 (31.3) 113 (43.9) 43 (53.1)
Note: QoL-AD = quality of life in Alzheimer’s disease; VAS = visual analogue scale.
Comorbidity and quality of life in dementia
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frequent conditions across the cohort were: hypertension
(38.7%); connective tissue disease (24.5%); depression
(15.4%); diabetes (12.7%); and chronic pulmonary disease
(12.5%). This pattern of prevalence was similar in both males
and females with the exception of the higher prevalence of
myocardial infarction in men (11.6%) vs. 5.3% in women.
Over 300 combinations of comorbid conditions were
found but most combinations had low frequencies (N < 10).
The most frequent two-way comorbidities were hypertension
with connective tissue disease (N = 43), hypertension and
diabetes (N = 24), and hypertension and depression (N =
22). Three-way comorbid combinations follow a similar
pattern with hypertension present in all three of the top com-
binations: hypertension, connective disease and diabetes
(N = 12); hypertension, cardiovascular disease and connect-
ive tissue disease (N = 8); and myocardial infarction, hyper-
tension and connective tissue disease (N = 7).
Table 1 reports the number of comorbid conditions by
sociodemographic factors. In total, 25% of the sample did
not report the presence of any comorbid condition. The
majority (52%) had mild (1–2 conditions) comorbidity and
only 5% had severe comorbidity (>5 conditions). The dis-
tribution was similar across gender and age groups but var-
ied across dementia subtypes. The percentage of vascular
dementia and mixed AD and VD subtypes increased with
the severity of comorbid conditions.
Table 2 reports the associations between level of
comorbidity and ratings on the QoL-AD and the EQ-5D.
There was a negative association between severity of
comorbid conditions and both QoL-AD and HRQoL
scores. Compared to those with no chronic conditions, par-
ticipants with severe comorbidity (≥5 conditions) had lower
QoL-AD by 6 points (−5.84; 95% CI: −7.27, −4.41) and
lower HRQoL scores by 18 points (−17.82; 95% CI:
−22.23, −13.42). After adjusting for age, sex, dementia sub-
types and education, the adjusted estimates were −5.07
(95% CI: −6.53, −3.62) for QoL-AD and −15.85 (95% CI:
−20.36, −11.34) for HRQoL.
For the five EQ5D domains severe comorbidity was
also associated with higher odds of moderate/severe pro-
blems in mobility (OR = 14.64; 95% CI:7.54, 28.41), self-
care issues (OR = 6.46; 95% CI: 3.44, 12.13), impairment
in usual activities (OR = 5.77; 95% CI: 3.28, 10.15), pain/
discomfort (OR = 8.51; 95% CI: 4.72, 15.36) and anxiety/
depression (OR = 2.81; 95% CI: 1.66, 4.74) after adjust-
ment for sociodemographic factors (Table 2).
Discussion
Using dementia as the index disease, this study examined
the co-occurrence and combinations of conditions in peo-
ple with dementia living in the community. The majority
0.0 10.0 20.0 30.0 40.0
Hypertension & Chronic Pulmonary…
Hypertension & Cancer
Hypertension & Depression
Hypertension & Cerebrovascular Disease
Hypertension & Diabetes
Hypertension and Connective Tissue…
Moderate/Severe Liver Disease
Hemiplegia
Lymphoma
Mild Liver Disease
Metastatic Cancer
Skin Ulcers/Cellulitis
Diabetes (end organ damage)
Moderate/Severe Renal Disease
Hypertension & Connective Tissue…
Ulcer Disease
Congestive Heart Failure
Myocardial Infarction
Peripheral Vascular Disease
Cancer (in past 5 years)
Chronic Pulmonary Disease
Diabetes
Cerebrovascular Disease
Depression
Connective Tissue Disease
Hypertension
Male n = 847
Female n = 655
Figure 1 Prevalence of comorbid conditions associated with dementia
S. M. Nelis et al.
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were living with one or two chronic health conditions, with
5% reporting more than five comorbidities. Hypertension
was the most frequent comorbid condition. The severity of
comorbid conditions was associated with lower both
HRQoL and dementia-specific QoL. People with severe
comorbid conditions had higher odds of problems in
mobility, self-care, managing usual activities, pain and
mood. The IDEAL cohort had similar rates of comorbidity
as those previously reported for people living with dementia
[6], with 74% of people reporting more than one condition.
Prevalence rates for comorbidity vary across living situation
and stages of dementia [7]. Comorbidities linked with
dementia identified through medical records report than
92% live with more than one condition [2]. Differences in
prevalence rates may be attributed to the broader range of
conditions encompassed in reviews of medical records than
those collected by self-report [3].
Comorbidities most prevalent in the dementia cohort
were hypertension, connective tissue disease, depression,
diabetes and chronic pulmonary disease. Combinations of
conditions included hypertension with connective tissue dis-
ease, diabetes and depression. Hypertension prevalence
rates are high in this age group [24]. For the main
comorbidities we identified there are known associations
between both Alzheimer’s disease and vascular dementia
and hypertension [25], and diabetes is a risk factor for
Alzheimer’s disease and dementia [26]. Depression in mid-
to late life has been linked with an increased risk of demen-
tia [27], and the prevalence of depression in people with
Alzheimer’s disease is high [28].
People with multiple chronic conditions were at greater
risk of health problems in mobility, self-care, usual activities,
pain/discomfort and anxiety/depression compared with
people living with dementia only. The severity of comorbid
conditions was negatively associated with global ratings of
HRQoL, consistent with previous studies [9, 13], and with
disease-specific assessment of QoL [15]. Previous research
has considered the impact of comorbidity in one QoL
domain [9] and this study provides additional evidence that
comorbidity may have a substantial impact on a person’s
subjective perception of ill health and perceptions of well-
being related to dementia.
There are some limitations in the measurement of
comorbidity within the study. Reliance on patient-reported
comorbidity may have led to the under-reporting of comorbid
conditions and confirmation with medical records is recom-
mended for future studies [29]. The CCI mainly considers
physical health conditions, and depression is the only mental
health condition included. Depression can have an independ-
ent negative impact on QOL as well as amplifying the impact
of physical conditions on perceived QOL [5]. The CCI does
not encompass other physical changes or challenges associated
with ageing (e.g. falls or frailty) that may also impact on QoL.
There is growing recognition of the importance of considering
frailty in combination with comorbidity [30], and this has also
extended to clinical guidelines [18]. A longitudinal perspective
on the impact of comorbidity as dementia progresses would
be useful, as the comorbidity may differ across stages of
dementia and new chronic conditions may arise.
Comorbidity in dementia may have serious implications
for well-being, and information on the nature of comorbid-
ity is needed to plan adequate support and interventions
[17]. The issue of comorbidity poses significant challenges
for care provision [4]. Dementia may impact on decision-
making and on the self-management of chronic conditions
[7]. There has been a move to identify groups at whom
interventions to deal with comorbidity should be targeted;
those at most risk are people who find it difficult to manage
everyday activities, those who are frail, and those who
receive care from multiple sources [18].
This study suggests that comorbidity is an important
risk factor for poor health and global well-being in people
with dementia. It is evident that people with dementia are
experiencing the impact of living with multiple diseases and
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Unadjusted and adjusted associations between
comorbidity, health-rated quality of life (EQ-5D) and qual-
ity of life (QoL-AD) and the five EQ-5D domains
Unadjusted model Adjusted model*
Coeff. (95% CI) Coeff. (95% CI)
QoL-AD
1–2 Mild vs. none −1.45 (−2.19, −0.70) −1.35 (−2.09, −0.62)
3–4 Moderate vs. none −4.16 (−5.13, −3.20) −4.07 (−5.05, −3.09)
≥5 Severe vs. none −5.84 (−7.27, −4.41) −5.07 (−6.53, −3.62)
EQ-5D VAS
1–2 Mild vs. none −5.15 (−7.43, −2.87) −4.85 (−7.13, −2.57)
3–4 Moderate vs.
none
−11.14 (−14.04, −8.24) −10.58 (−13.53, −7.63)
≥5 Severe vs. none −17.82 (−22.23, −13.42) −15.85 (−20.36, −11.34)
EQ-5D domains OR (95% CI) OR (95% CI)
EQ-5D mobility
1–2 Mild vs. none 2.18 (1.64, 2.90) 1.98 (1.46, 2.68)
3–4 Moderate vs. none 5.27 (3.71, 7.48) 4.44 (3.06, 6.45)
≥5 Severe vs. none 16.14 (8.63, 30.18) 14.64 (7.54, 28.41)
EQ-5D self-care
1–2 Mild vs. none 1.77 (1.18, 2.67) 1.85 (1.20, 2.87)
3–4 Moderate vs. none 3.86 (2.46, 6.05) 4.50 (2.75, 7.37)
≥5 Severe vs. none 6.89 (3.90, 12.18) 6.46 (3.44, 12.13)
EQ-5D usual activities
1–2 Mild vs. none 1.33 (1.00, 1.78) 1.24 (0.90, 1.69)
3–4 Moderate vs. none 2.71 (1.92, 3.83) 2.44 (1.68, 3.55)
≥5 Severe vs. none 6.44 (3.82, 10.85) 5.77 (3.28, 10.15)
EQ-5D Pain/discomfort
1–2 Mild vs. none 2.06 (1.55, 2.73) 1.97 (1.47, 2.64)
3–4 Moderate vs. none 3.60 (2.56, 5.08) 3.43 (2.38, 4.92)
>5 Severe vs. none 9.56 (5.46, 16.73) 8.51 (4.72, 15.36)
EQ-5D Anxiety/Depression
1–2 Mild vs. none 1.13 (0.86, 1.49) 1.18 (0.89, 1.58)
3–4 Moderate vs. none 1.96 (1.40, 2.74) 2.17 (1.52, 3.10)
≥5 Severe vs. none 2.83 (1.72, 4.62) 2.81 (1.66, 4.74)
*Adjusted for age group, sex, dementia subtypes and education.
Note: QoL-AD = quality of life in Alzheimer’s disease; VAS = visual analogue
scale.
Comorbidity and quality of life in dementia
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there is need for greater support and intervention in care
provision and planning. Care providers often focus on indi-
vidual conditions and this study highlights the need for bet-
ter care planning and the organisation of care provision to
deal with multiple conditions in an integrated way. The
presence of multiple conditions is likely to increase the bur-
den on carers who support people with dementia and the
implications of this additional responsibility for carers
should also be considered.
Key points
• The majority of people with dementia were living with
one or two chronic health conditions, and hypertension
was the most frequent comorbid condition.
• Multiple health conditions have important consequences
for the quality of life (QoL) and well-being of the
individual.
• This study highlights the need for better care planning
and the organisation of care provision to deal with mul-
tiple conditions in an integrated way.
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